Psyence Biomedical Ltd. PBM
Nov 4, 2026, 9:30 AM EST
- YTD
- -88.30%
- 1 year
- -97.06%
- Market cap
- 13.12M
- EPS (ttm)
- -13.29
- Shares out
- 845.06K
- YTD return
- -88.30%
- 1-year return
- -97.06%
- Volume
- 1.21K
- Avg volume
- 79.45K
- Open
- 3.44
- Previous close
- 3.29
- Day's range
- 3.44 – 3.44
- 52-week range
- 1.92 – 116.41
- Beta
- -0.42
YTD -27.92 (-89.46%)
Key statistics
- Enterprise value
- 49.51M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -1.71M
- Total cash
- 733.19K
- Total debt
- 7.66M
- Return on equity
- 0.00%
- Short % of float
- 1.34%
- 50-day average
- 4.68
- 200-day average
- 36.44
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- psyencebiomed.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896 
Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient 
Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S. 
Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Psyence BioMed Establishes Active Ibogaine Operations, Production Capabilities In Africa 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For ~150M
Your note
Sign in to keep a note on PBM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 5, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 0.03% | 16,431 | 39.10K | Sep 29, 2024 |
| Cantor Fitzgerald, L.P. | 0.01% | 4,493 | 10.69K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.00% | 2,257 | 5.37K | Sep 29, 2024 |
| Stonehage Fleming Financial Services Holdings Limited | 0.00% | 1,073 | 2.55K | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 645 | 1.53K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.00% | 613 | 1.46K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.04% | 25,272 | 60.15K | Oct 30, 2024 |